Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 22, 2024. The document announced the availability of a final guidance for industry entitled "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment." The document was published with an incorrect docket number. This document corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 48 (Monday, March 11, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 48 (Monday, March 11, 2024)]
[Notices]
[Page 17475]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-05081]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-D-1824]
Assessing COVID-19-Related Symptoms in Outpatient Adult and
Adolescent Subjects in Clinical Trials of Drugs and Biological Products
for COVID-19 Prevention or Treatment; Guidance for Industry; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register on February 22, 2024. The
document announced the availability of a final guidance for industry
entitled ``Assessing COVID-19-Related Symptoms in Outpatient Adult and
Adolescent Subjects in Clinical Trials of Drugs and Biological Products
for COVID-19 Prevention or Treatment.'' The document was published with
an incorrect docket number. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: David Reasner, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 6373, Silver Spring, MD 20993, 301-837-
7667; or James Myers, Center for Biologics Evaluation and Research,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm.
7301, Silver Spring, MD 20993-0002, 240-402-7911.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 22, 2024
(89 FR 13351), in FR Doc. 2024-03622, the following correction is made:
On page 13351, in the first column in the header of the document
and in the third column in the second line of the first paragraph,
``Docket No. FDA-2024-D-0584'' is corrected to read ``Docket No. FDA-
2020-D-1824.''
Dated: March 5, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-05081 Filed 3-8-24; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.